Chun Tae-Wook, Justement J Shawn, Moir Susan, Hallahan Claire W, Maenza Janine, Mullins James I, Collier Ann C, Corey Lawrence, Fauci Anthony S
Laboratory of Immunoregulation, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Infect Dis. 2007 Jun 15;195(12):1762-4. doi: 10.1086/518250. Epub 2007 May 2.
The persistence of latently infected resting CD4+ T cells has been clearly demonstrated in human immunodeficiency virus (HIV)-infected individuals receiving effective antiviral therapy. However, estimates of the half-life of this viral reservoir have been quite divergent. We demonstrate clear evidence for decay of this HIV reservoir in patients who initiated antiviral therapy early in infection. The half-life of this latent viral reservoir was estimated to be 4.6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection.
在接受有效抗病毒治疗的人类免疫缺陷病毒（HIV）感染者中，潜伏感染的静止CD4 + T细胞的持续存在已得到明确证实。然而，对这个病毒储存库半衰期的估计却大不相同。我们在感染早期就开始接受抗病毒治疗的患者中发现了该HIV储存库衰减的明确证据。这个潜伏病毒储存库的半衰期估计为4.6个月。据推测，对于在HIV感染早期就开始接受抗病毒治疗的感染者，要完全清除潜伏感染的静止CD4 + T细胞，需要长达7.7年的持续治疗。
